- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01181895
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
9 oktober 2017 bijgewerkt door: GlaxoSmithKline
A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.
Studie Overzicht
Toestand
Voltooid
Conditie
Studietype
Ingrijpend
Inschrijving (Werkelijk)
348
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Bayern
-
Gauting, Bayern, Duitsland, 82131
- GSK Investigational Site
-
-
Hessen
-
Frankfurt, Hessen, Duitsland, 60596
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Duitsland, 55131
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Grosshansdorf, Schleswig-Holstein, Duitsland, 22927
- GSK Investigational Site
-
-
-
-
-
Dnipropetrovsk, Oekraïne, 49074
- GSK Investigational Site
-
Dnipropetrovsk, Oekraïne, 49027
- GSK Investigational Site
-
Donetsk, Oekraïne, 83099
- GSK Investigational Site
-
Ivano-Frankivsk, Oekraïne, 76018
- GSK Investigational Site
-
Kharkiv, Oekraïne, 61124
- GSK Investigational Site
-
Kharkiv, Oekraïne, 61037
- GSK Investigational Site
-
Kyiv, Oekraïne, 03680
- GSK Investigational Site
-
Simferopol, Oekraïne, 95043
- GSK Investigational Site
-
Yalta, Oekraïne, 98603
- GSK Investigational Site
-
-
-
-
-
Lima, Peru, Lima 27
- GSK Investigational Site
-
-
Lima
-
Callao, Lima, Peru, Callao 2
- GSK Investigational Site
-
Lima 27, Lima, Peru, Lima 27
- GSK Investigational Site
-
San Isidro, Lima, Peru, Lima 27
- GSK Investigational Site
-
San Miguel, Lima, Peru, Lima 32
- GSK Investigational Site
-
-
-
-
-
Chrzanow, Polen, 32-500
- GSK Investigational Site
-
Krakow, Polen, 31-024
- GSK Investigational Site
-
Krakow, Polen, 31-455
- GSK Investigational Site
-
Krakow, Polen, 30-901
- GSK Investigational Site
-
Lublin, Polen, 20-552
- GSK Investigational Site
-
-
-
-
California
-
Huntington Beach, California, Verenigde Staten, 92647
- GSK Investigational Site
-
-
Florida
-
Orlando, Florida, Verenigde Staten, 32822
- GSK Investigational Site
-
Tallahassee, Florida, Verenigde Staten, 32308
- GSK Investigational Site
-
-
Georgia
-
Lawrenceville, Georgia, Verenigde Staten, 30046
- GSK Investigational Site
-
-
New Jersey
-
Skillman, New Jersey, Verenigde Staten, 08558
- GSK Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, Verenigde Staten, 27607
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45231
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73103
- GSK Investigational Site
-
-
South Carolina
-
Chester, South Carolina, Verenigde Staten, 29706
- GSK Investigational Site
-
Clinton, South Carolina, Verenigde Staten, 29325
- GSK Investigational Site
-
Orangeburg, South Carolina, Verenigde Staten, 29118
- GSK Investigational Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
12 jaar en ouder (Kind, Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Outpatient at least 12 years of age
- Both genders; females of childbearing potential must be willing to use birth control method
- Clinical diagnosis of asthma for ≥12 weeks
- Best pre-bronchodilator FEV1 of 40%-90% predicted
- Reversibility of FEV1 of at least 12% and 200mls
- Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit
- Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits
Exclusion Criteria:
- History of life-threatening asthma
- Respiratory infection within last 4 weeks leading to change in asthma management
- Asthma exacerbation within last 3 months
- Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
- Allergies to study drugs, study drugs' excipients, or medications related to study drugs
- Taking another investigational medication or medication prohibited for use during the study.
- Previous participation in a vilanterol (GW642444) study
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Vilanterol
Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
|
Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Placebo inhalation powder inhaled orally twice daily for 12 weeks
|
|
Actieve vergelijker: Salmeterol
Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
|
Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
|
|
Placebo-vergelijker: Placebo
Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
|
Placebo inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12
Tijdsspanne: Baseline and Week 12
|
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second.
The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12.
The Baseline value was the Day 1 pre-dose FEV1 measurement.
Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value.
Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
|
Baseline and Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
Tijdsspanne: Baseline and Weeks 1-12
|
The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period.
The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization).
Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Tijdsspanne: Baseline and Weeks 1-12
|
Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed.
The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization).
Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points
Tijdsspanne: Baseline and Week 12
|
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second.
The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12).
The Baseline value was the Day 1 pre-dose FEV1 measurement.
Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value.
Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
Analysis was performed separately for each planned time point.
|
Baseline and Week 12
|
|
Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Tijdsspanne: Baseline and Weeks 1-12
|
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated.
Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug.
The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization.
Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period
Tijdsspanne: Baseline and Weeks 1-12
|
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated.
Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug.
The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization.
Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)
Tijdsspanne: Day 1 and Week 12
|
The number of participants with a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a >=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points.
Participants who did not achieve a >=12% and >=200 mL increase from Baseline in FEV1 over this time period were considered censored.
|
Day 1 and Week 12
|
|
Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12
Tijdsspanne: Week 4 and Week 12
|
At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.
|
Week 4 and Week 12
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 september 2010
Primaire voltooiing (Werkelijk)
1 augustus 2011
Studie voltooiing (Werkelijk)
26 augustus 2011
Studieregistratiedata
Eerst ingediend
15 juli 2010
Eerst ingediend dat voldeed aan de QC-criteria
12 augustus 2010
Eerst geplaatst (Schatting)
13 augustus 2010
Updates van studierecords
Laatste update geplaatst (Werkelijk)
8 november 2017
Laatste update ingediend die voldeed aan QC-criteria
9 oktober 2017
Laatst geverifieerd
1 oktober 2017
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van de luchtwegen
- Ziekten van het immuunsysteem
- Longziekten
- Overgevoeligheid, Onmiddellijk
- Bronchiale ziekten
- Longziekten, obstructief
- Ademhalingsovergevoeligheid
- Overgevoeligheid
- Astma
- Fysiologische effecten van medicijnen
- Adrenerge middelen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Autonome agenten
- Agenten van het perifere zenuwstelsel
- Adrenerge agonisten
- Bronchusverwijdende middelen
- Anti-astmatische middelen
- Agenten van het ademhalingssysteem
- Adrenerge bèta-2-receptoragonisten
- Adrenerge beta-agonisten
- Salmeterol Xinafoaat
Andere studie-ID-nummers
- 112060
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Bestudeer gegevens/documenten
-
Klinisch onderzoeksrapport
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Geannoteerd casusrapportformulier
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulier geïnformeerde toestemming
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisch analyseplan
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Gegevensset individuele deelnemers
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Leerprotocool
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Specificatie gegevensset
Informatie-ID: 112060Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .